Results 171 to 180 of about 35,534 (303)

A high-throughput screening platform to identify MYCN expression inhibitors for liver cancer therapy

Frontiers in Oncology
MYCN, an oncogene implicated in hepatocellular carcinoma (HCC), is predominantly expressed in cancer stem-like HCC cells. It drives tumorigenicity, metastasis, and therapeutic resistance. In this study, we hypothesized that the pharmacological inhibition
Yali Xu, Yali Xu, Hricha Mishra, Yutaka Furutani, Kaori Yanaka, Hajime Nishimura, Erina Furuhata, Masataka Takahashi, Luc Gailhouste, Yusuke Suenaga, Yoshitaka Hippo, Wenkui Yu, Tomokazu Matsuura, Harukazu Suzuki, Xian-Yang Qin   +14 more
doaj   +1 more source

Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation [PDF]

, 2004
Culp, Lloyd A, Edsjö, Anders,, Karlsson, Jenny,, Lund University., Nilsson, Helén,, Pattyn, Filip, Påhlman, Sven,, Speleman, Frank, Vandesompele, Jo   +8 more
core   +2 more sources

Decision letter for "Growth inhibition and suppression of the mTOR and Wnt/beta-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion"

, 2020

openalex   +1 more source

Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases [PDF]

, 2019
Lucia Mundo, Maria Raffaella Ambrosio, Francesco Raimondi, Leonardo Del Porro, Raffaella Guazzo, Virginia Mancini, Massimo Granai, Bruno Jim Rocca, Cristina López, Susanne Bens, Noel Onyango, Joshua Nyagol, Nicholas Abinya, Mohsen Navari, Isaac Ndede, Kirkita Patel, Pier Paolo Piccaluga, Roshanak Bob, Maria Margherita De Santi, Robert B. Russell, Stefano Lazzi, Reiner Siebert, Harald Stein, Lorenzo Leoncini   +23 more
openalex   +1 more source

Oxphos Targeting of Mycn -Amplified Neuroblastoma [PDF]

Soraya Epp, Donagh Egan, Evon Poon, Amirah Adlina Abdul Aziz, Kieran Wynne, Melinda Halász, Walter Kölch, Walter Kolch   +7 more
openalex   +1 more source

Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified Neuroblastoma [PDF]

, 2019
Jacob Bellamy, Marianna Szemes, Zsombor Melegh, Anthony R. Dallosso, Madhu Kollareddy, Daniel Catchpoole, Karim Malik   +6 more
openalex   +1 more source

MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system [PDF]

, 2014
Marco Gessi, André O. von Bueren, András Treszl, Anja zur Mühlen, Wolfgang Hartmann, Monika Warmuth‐Metz, Stefan Rutkowski, Torsten Pietsch   +7 more
openalex   +1 more source

MYCN in human development and diseases

Frontiers in Oncology
Somatic mutations in MYCN have been identified across various tumors, playing pivotal roles in tumorigenesis, tumor progression, and unfavorable prognoses. Despite its established notoriety as an oncogenic driver, there is a growing interest in exploring the involvement of MYCN in human development.
Yosuke Nishio, Yosuke Nishio, Yosuke Nishio, Kohji Kato, Kohji Kato, Kohji Kato, Hisashi Oishi, Yoshiyuki Takahashi, Shinji Saitoh   +8 more
openaire   +3 more sources

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy

, 2017
Brian H. Kushner, Michael P. LaQuaglia, Shakeel Modak, Suzanne L. Wolden, Ellen M. Basu, Stephen S. Roberts, Kim Kramer, Karima Yataghene, Irene Y. Cheung, Nai‐Kong V. Cheung   +9 more
openalex   +2 more sources

Additional file 6: Table S5. of Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance

, 2017
David J. Duffy, Aleksandar Krstić, Melinda Halász, Thomas Schwarzl, Anja Konietzny, Kristiina Iljin, Desmond G. Higgins, Walter Kölch   +7 more
openalex   +1 more source